| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 18 May 2026 | 11 May 2026 |
| Final Dividend & Audited Results Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 18, 2026, inter alia: 1. to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and financial year ended March 31, 2026; and 2. to consider and recommend final dividend, if any, on equity shares of the Company for the financial year ended March 31, 2026. Further, as per the provisions of Companys Code of Conduct for Prohibition of Insider Trading, trading window for Designated Persons of the Company has been closed from April 1, 2026 and shall open after 48 hours post declaration of financial results by the Company. Outcome of Board Meeting of the Company held on May 18, 2026 Update with regard to our intimation dated May 18, 2026 regarding movement in Board of Directors, KMP and SMP of the Company (As Per BSE Announcement Dated on 18.05.2026) | ||
| Board Meeting | 30 Jan 2026 | 23 Jan 2026 |
| Quarterly Results Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 ,inter alia, to consider and approve Intimation regarding Board Meeting under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Unaudited financial results for quarter and nine months ended December 31, 2025 (As Per BSE Announcement Dated on: 30/01/2026) | ||
| Board Meeting | 31 Oct 2025 | 24 Oct 2025 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 inter alia to consider and approve Intimation regarding Board Meeting under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Outcome of Board Meeting - Unaudited Financial Results (Consolidated & Standalone) for the quarter and half year ended September 30, 2025 (As Per BSE Announcement Dated on:31.10.2025) | ||
| Board Meeting | 29 Jul 2025 | 23 Jul 2025 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2025 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday July 29 2025 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended June 30 2025 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed from July 1 2025 and shall open after 48 hrs post declaration of financial results by the Company. Financial Results (Consolidated & Standalone) for the quarter ended June 30, 2025 Allotment of shares under the ESOP Scheme (As Per BSE Announcement Dated on :29.07.2025) | ||
Kenox, a contract drug maker with a focus on inhaled and nasal products, will handle formulation and development, while Strides brings in manufacturing scale and market access.
Here are some of the stocks that may see significant price movement today: Infosys, Brigade Enterprises, Strides Pharma, etc.
EBITDA grew 48% YoY at ₹210 crore, from ₹142 crore in the same quarter last year, marking better profitability.
EBITDA rose significantly to ₹235.7 Crore, a 54% increase from ₹153 Crore in the corresponding period of the previous year.
In September 2023, the pharmaceutical behemoth revealed OneSource. The stock exchanges approved the idea earlier this year, in May.
The medication is bioequivalent and therapeutically equivalent to Schering Corp's Reference Listed Drug (RLD), THEO-DUR.
The Alathur facility is key to Strides' global operations, especially in the US and other regulated markets, specializing in the production of tablets and capsules.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
